Royalty Payable	9 Months Ended
Sep. 30, 2019
Payables and Accruals [Abstract]
Royalty Payable	Royalty Payable The Company entered into various agreements and subsequently received funding from investors for use by the Company for the research and development of its Opioid Overdose Reversal Treatment Product ("OORTP"). In exchange for this funding, the Company agreed to provide investors with interest in the OORTP Net Profit generated from its OORTP in perpetuity. As of December 31, 2018, the Company determined an OORTP Net Profit as a result of NARCAN® sales by Adapt and recorded a royalty payable of $1.0 million. In connection with these agreements and a senior advisor agreement, the Company also granted net profit interests in DAVINCI (as defined in the related agreements) (the "DAVINCI interest"). The Company has buy back rights to the DAVINCI interest which it exercised during the nine months ended September 30, 2019 for a total consideration of approximately $1.25 million. As of September 30, 2019, the Company has a royalty payable of approximately $4.5 million, of which approximately $878 thousand is related to the buy-back liability.

Royalty Payable

The Company entered into various agreements and subsequently received funding from investors for use by the Company for the research and development of its Opioid Overdose Reversal Treatment Product ("OORTP"). In exchange for this funding, the Company agreed to provide investors with interest in the OORTP Net Profit generated from its OORTP in perpetuity. As of December 31, 2018, the Company determined an OORTP Net Profit as a result of NARCAN® sales by Adapt and recorded a royalty payable of $1.0 million. In connection with these agreements and a senior advisor agreement, the Company also granted net profit interests in DAVINCI (as defined in the related agreements) (the "DAVINCI interest"). The Company has buy back rights to the DAVINCI interest which it exercised during the nine months ended September 30, 2019 for a total consideration of approximately $1.25 million. As of September 30, 2019, the Company has a royalty payable of approximately $4.5 million, of which approximately $878 thousand is related to the buy-back liability.